Skuldtech scores additional EUR 1 million from Bpifrance for Alzheimer’s disease project

Biotechnology firm Skuldtech announced that it received EUR 1 million or USD 1.3 million from French public investment bank Bpifrance (Banque publique d’investissement). The funding was given to develop a new therapy for treating Alzheimer’s disease, which is Skuldtech’s current project. The latest amount brought the total funding of the project to EUR 8.6 million. The program was set for four years, with 2018 as the target date for the first results of the therapy.

Read full articles: